Locations:
Search IconSearch
December 29, 2021/Cancer/Patient Support

Managing Intractable Nausea and Vomiting in the Palliative Care Setting

Identifying the underlying cause key to successful treatment

Nausea

A recent article published in American Academy of Hospice and Palliative Medicine provides an overview of approaches for treating intractable nausea and vomiting in the palliative care setting. Published by Cleveland Clinic palliative medicine specialist Kyle Neale, DO, the article explains that nausea and vomiting are best addressed using a mechanistic approach focused on uncovering the underlying cause of the patient’s symptoms.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Addressing multifactorial causes

There are multiple culprits for nausea and vomiting, particularly in the palliative care and oncology populations, including chemotherapy, anxiety, constipation, delayed motility of the gastrointestinal tract and functional bowel disorder. Although a number of medications can be trialed to alleviate the patient’s symptoms, Dr. Neale says there is no one-size-fits-all approach. The key, he explains, is to properly diagnose and treat the underlying cause by incorporating medications of different classes when needed.

“For chemotherapy-related nausea and vomiting, we usually prescribe ondansetron or prochlorperazine; we may occasionally escalate to a longer-acting drug like olanzapine,” explains Dr. Neale, a staff physician in Taussig Cancer Institute. For patients with anticipatory anxiety, drugs like lorazepam can be used to manage panic or anxiety episodes. Metoclopramide can also be helpful for encouraging motility and mitigating nausea.”

Many of the drugs clinicians have historically used to treat nausea and vomiting were originally designed for other purposes, he adds.

“For example, metoclopramide was initially derived to encourage motility in patients with poorly controlled diabetes, but it’s actually a very effective nausea drug as well. Olanzapine is actually an antipsychotic; at lower doses, however, it can be highly effective for managing severe chemotherapy-induced nausea and vomiting.”

Dr. Neale emphasizes that when there are several reasons behind a patient’s symptoms, an appropriate therapeutic regimen should be prescribed based on each medication’s mechanism of action.

Advertisement

“We know that the neurotransmitters in the area of the brain that promote nausea and vomiting are affected by many common medicines, so potential overlap should be considered,” he says. “For example, olanzapine targets many different neurotransmitters – a nice benefit that enables us to cover a lot of bases when several different causes of nausea are suspected.”

Ensuring safe treatment

“In most cases, nausea and vomiting can be well-controlled with medication, so providing relatively rapid relief is simply a matter of finding the right treatment,” explains Dr. Neale. In general, nausea and vomiting are managed for as long as the underlying cause is present, but patients rarely require ongoing treatment.

Although available drugs for treating nausea and vomiting are quite safe, Dr. Neale cautions that care must be taken when adding medications to the patient’s existing drug regimen.

“We’re cautious when combining some of these drugs because of their potential to cause irreversible neurologic interactions in the long-term,” he says. “As a result, we judiciously avoid prescribing treatments that trigger too much of a dopamine or serotonin response. We also have to be careful that a patient’s other medications – particularly antidepressants and other antiemetics – are not activating too many of those neurotransmitters.”

Patients who are interested in incorporating complementary therapies such as meditation, acupuncture and aromatherapy are encouraged to explore options available through the Cleveland Clinic Center for Functional Medicine.

Advertisement

Finally, Dr. Neale encourages patients to speak up if their nausea and vomiting persists. “If the first medication does not work, other options are available,” he says.

Advertisement

Related Articles

Hands after RT
January 30, 2026/Cancer/Radiation Oncology
Patient Case Study: Radiation Therapy Used to Treat Dupuytren's Disease

Radiation therapy helped shrink hand nodules and improve functionality

Dr. Ali and patient
January 29, 2026/Cancer/News & Insight
Real-World Data Reveals Gap Between Guidelines and Practice in HER2+ Breast Cancer Care

Standard of care is linked to better outcomes, but disease recurrence and other risk factors often drive alternative approaches

Dr. Thomas Budd
January 28, 2026/Cancer/Innovations
Breast Cancer Vaccine Moves One Step Forward

Phase 1 study demonstrates immune response in three quarters of patients with triple-negative breast cancer

Dr. Mukhejee and colleagues
January 22, 2026/Cancer/News & Insight
Rare Cancers and Blood Disease Program Accelerates Diagnostic Journey

Multidisciplinary teams bring pathological and clinical expertise

genetic test
January 16, 2026/Cancer/News & Insight
Five Percent of U.S. Population Carries Pathogenic Variants Associated with Cancer Risk

Genetic variants exist irrespective of family history or other contributing factors

GLP-1
January 12, 2026/Cancer/Blood Cancers
GLP-1a Therapy Improves Survival in Patients with Polycythemia Vera and Myelodysplastic Syndromes

Study shows significantly reduced risk of mortality and disease complications in patients receiving GLP-1 agonists

Oncology nurse
January 9, 2026/Cancer
Improving Patient Experience in Inpatient Hematology: A Nursing Perspective

Structured interventions enhance sleep, safety and caregiver resiliency in high-acuity units

PET scan
January 7, 2026/Cancer/Blood Cancers
Case Study: 21-Year-Old Patient with Refractory T-Cell Lymphoma

Addressing rare disease and challenging treatment course in an active young patient

Ad